SMi's 7th annual Orphan Drugs and Rare Diseases UK Conference
Date: | 18-Oct-17 to 19-Oct-17 |
Location: | Holiday Inn Kensington Forum / London / United Kingdom |
Category: | Healthcare & Pharmaceuticals Conferences & Trade Fairs |
SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
Aimed at an audience of senior scientists and oncology specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and repurposing.
Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts.
Featured Speakers:
• Olivier Morand, Clinical Science Program Head, Actelion Pharmaceuticals
• Larissa Kerecuk, Rare Disease Lead, Consultant Paediatric Nephrologist, Birmingham Children’s Hospital
• Oliver Timmis, CEO, AKU Society
• Stuart Hughes, Director, Head of Pharmacology, Vertex
• Christine Lavery, Group Chief Executive, MPS Society
• Olaf Ritzeler, External Innovation Lead, Sanofi
• Stephen Marcus, CEO, Cantex Pharmaceuticals
Exclusive highlights in 2017:
• Learn about new therapies for different rare diseases, and how these can successfully be applied to other diseases with similar attributes
• Hear what opportunities and challenges come with working on rare diseases, as well as the development of the world’s first rare disease centre for children
• Expand your knowledge on patient collaboration and patient centric models with the stream on patient engagement
Aimed at an audience of senior scientists and oncology specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and repurposing.
Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts.
Featured Speakers:
• Olivier Morand, Clinical Science Program Head, Actelion Pharmaceuticals
• Larissa Kerecuk, Rare Disease Lead, Consultant Paediatric Nephrologist, Birmingham Children’s Hospital
• Oliver Timmis, CEO, AKU Society
• Stuart Hughes, Director, Head of Pharmacology, Vertex
• Christine Lavery, Group Chief Executive, MPS Society
• Olaf Ritzeler, External Innovation Lead, Sanofi
• Stephen Marcus, CEO, Cantex Pharmaceuticals
Exclusive highlights in 2017:
• Learn about new therapies for different rare diseases, and how these can successfully be applied to other diseases with similar attributes
• Hear what opportunities and challenges come with working on rare diseases, as well as the development of the world’s first rare disease centre for children
• Expand your knowledge on patient collaboration and patient centric models with the stream on patient engagement
Exhibitors
ADB Medical, Chiesi Farmaceutici S.p.A., Sanofi, Summit Therapeutics, Findacure, AKU Society, GlaxoSmithKline, Vertex Pharmaceuticals, MPS Society, Birmingham Children's Hospital, Deutsches Krebsforschungszentrum, Alexion Pharma GmbH, Cantex Pharmaceuticals, Actelion Pharmaceuticals, Action Duchenne, Selecta Biosciences, Cambridge Rare Disease Network (CRDN), Birmingham Children's Hospital
EIN News
provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See:
- Autism News Today
- Brain Cancer News Today
- Breast Cancer News Today
- Breastfeeding News Today
- Conferences & Trade Shows Today
- Dental Industry Today
- Dietary Supplements News Today
- H1N1 News Today
- H7N9 Bird Flu News Today
- Health Insurance Exchanges News
- Healthcare Industry Today
- Healthcare Reform News Today
- Home Birth News Today
- Lung Cancer News Today
- MERS News Today
- Malaria News Today
- Marijuana News Today
- Mesothelioma News Today
- Pharmaceutical Industry Today
- Planned Parenthood News Today
- Prostate Cancer News Today
- SARS News Today
- Wellness News Today